• Sanchia S. Goonewardene
  • Raj Persad


The searches identified 580 papers (Fig. 115.1). However, only ten mapped to the search terms and eligibility criteria. The current systematic reviews were also examined to gain further knowledge about the subject. Five hundred and eighty papers were excluded due to not conforming to eligibility criteria or adding to the evidence for psychosexual pathways or components of pathways for men with prostate cancer, post-surgery. Results were presented as per PRISMA criteria [1]. Of the ten papers left, relevant abstracts were identified and the full papers obtained (all of which were in English), to quality assure against criteria. There was significant heterogeneity within studies, including clinical topic, numbers, outcomes, as a results a narrative review was thought to be best.


  1. 1.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Online). 2009;339:332–6.Google Scholar
  2. 2.
    Thomas R, Williams M, Bellamy P. A polyphenol rich whole food supplement reduces PSA progression in men with prostate cancer in a double blind placebo controlled RCT-the UK National Pomi-T Study. Support Care Cancer. 2013;21:S33–4.Google Scholar
  3. 3.
    Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs AS, DeWeese T, Carducci M, Basaria S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009;182:2265–73.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Caso J, Masko EM, Ii JAT, Poulton SH, Dewhirst M, Pizzo SV, Freedland SJ. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013;73:449–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Westerlund A, Steineck G, Balter K, Stattin P, Gronberg H, Hedelin M. Dietary supplement use patterns in men with prostate cancer: The Cancer Prostate Sweden Study. Ann Oncol. 2011;22:967–72.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013;64:159–66.CrossRefGoogle Scholar
  7. 7.
    Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63:709–16.CrossRefGoogle Scholar
  8. 8.
    Ziaran S, Goncalves FM, Sn JB. Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:33–8.CrossRefGoogle Scholar
  9. 9.
    Lebret T, Coloby P, Descotes JL, Droupy S, Geraud M, Tombal B. Educational tool-kit on diet and exercise: Survey of prostate cancer patients about to receive androgen deprivation therapy. Urology. 2010;76:1434–9.CrossRefGoogle Scholar
  10. 10.
    Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10:6–20.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
  • Raj Persad
    • 2
  1. 1.The Royal Free Hospital and UCLLondonUnited Kingdom
  2. 2.North Bristol NHS TrustBristolUnited Kingdom

Personalised recommendations